Promoting apoptosis as a strategy for cancer drug discovery (original) (raw)

• Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456–1462 (1995).
  Article CAS PubMed Google Scholar
• Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205–219 (2004).
  CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810–816 (2000).
  CAS PubMed Google Scholar
• Nagata, S. Apoptosis by death factor. Cell 88, 355–365 (1997).
  CAS PubMed Google Scholar
• Budihardjo, I., Oliver, H., Lutter, M., Luo, X. & Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15, 269–290 (1999).
  CAS PubMed Google Scholar
• Baell, J. B. & Huang, D. C. S. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol. 64, 851–863 (2002).
  CAS PubMed Google Scholar
• Deveraux, Q. L., Takahashi, R., Salvesen, G. S. & Reed, J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388, 300–304 (1997).
  CAS PubMed Google Scholar
• Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome _c_-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33–42 (2000).
  CAS PubMed Google Scholar
• Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43–53 (2000).
  CAS PubMed Google Scholar
• Chene, P. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 3, 102–109 (2003).
  CAS Google Scholar
• Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Rev. Cancer 2, 420–421 (2002).
  CAS Google Scholar
• Hymowitz, S. G. et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4, 563–571 (1999).
  CAS PubMed Google Scholar
• Mongkolsapaya, J. et al. Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotis initiation. Nature Struct. Biol. 6, 1048–1053 (1999).
  CAS PubMed Google Scholar
• Cha, S. S. et al. Crystal structure of TRAIL–DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J. Biol. Chem. 275, 31171–31177 (2000).
  CAS PubMed Google Scholar
• Kelley, S. K. & Ashkenazi, A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4, 333–339 (2004). A comprehensive review on targeting TRAIL receptors.
  CAS PubMed Google Scholar
• Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891–4898 (2001).
  CAS PubMed Google Scholar
• Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med. 7, 954–960 (2001).
  CAS PubMed Google Scholar
• Takeda, K. et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437–448 (2004).
  CAS PubMed PubMed Central Google Scholar
• Presta, L. G. Engineering antibodies for therapy. Curr. Pharm. Biotechnol. 3, 237–256 (2002).
  CAS PubMed Google Scholar
• Shankar, S., Chen, X. & Srivastava, R. K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62, 165–186 (2005).
  CAS PubMed Google Scholar
• Inoue et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11, S193–S206 (2004).
  CAS PubMed Google Scholar
• Naka, T. et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62, 5800–5806 (2002).
  CAS PubMed Google Scholar
• Pollack, I. F., Erff, M. & Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res. 7, 1362–1369 (2001).
  CAS PubMed Google Scholar
• Jin, H. et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 64, 4900–4905 (2004).
  CAS PubMed Google Scholar
• Ray, S. & Almasan, A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63, 4713–4723 (2003).
  CAS PubMed Google Scholar
• Mitsiades, C. S. et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795–804 (2001).
  CAS PubMed Google Scholar
• Chinnaiyan, A. M. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl Acad. Sci USA 97, 1754–1759 (2000).
  CAS PubMed PubMed Central Google Scholar
• Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155–162 (1999).
  CAS PubMed PubMed Central Google Scholar
• Kelley, S. K. et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299, 31–38 (2001).
  CAS PubMed Google Scholar
• LeBlanc, H. N. & Ashkenazi, A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66–75 (2003).
  CAS PubMed Google Scholar
• Jin, Z., McDonald III, E. R., Dicker, D. T. & El-Deiry, W. S. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279, 35829–35839 (2004).
  CAS PubMed Google Scholar
• Kazhdan, I. & Marciniak, R. A. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Gene Ther. 11, 691–698 (2004).
  CAS PubMed Google Scholar
• Chawla-Sarkar, M. et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11, 915–923 (2004).
  CAS PubMed Google Scholar
• Fulda, S., Wick, W., Weller, M. & Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Med. 8, 808–815 (2002).
  CAS PubMed Google Scholar
• LeBlanc, H. et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nature Med. 8, 274–281 (2002).
  CAS PubMed Google Scholar
• Deng, Y., Lin, Y. & Wu, X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16, 33–45 (2002).
  CAS PubMed PubMed Central Google Scholar
• Ravi, R. & Bedi, A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-xL. Cancer Res. 62, 1583–1587 (2002).
  CAS PubMed Google Scholar
• Kelekar, A. & Thompson, C. B. Bcl-2 family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 8, 324–330 (1998).
  CAS PubMed Google Scholar
• Huang, D. C. & Strasser, A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 103, 839–842 (2000).
  CAS PubMed Google Scholar
• Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730 (2001).
  CAS PubMed PubMed Central Google Scholar
• Petros, A. M., Olejniczak, E. T. & Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83–94 (2004).
  CAS PubMed Google Scholar
• Sattler, M. et al. Structure of Bcl-xL–Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986 (1997). First structure that defined pro- and anti-apoptotic BCL2 family members interacting with one another.
  CAS PubMed Google Scholar
• Petros, A. M. et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 9, 2528–2534 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kirkin, V., Joos, S. & Zornig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644, 229–249 (2004).
  CAS PubMed Google Scholar
• Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097–1099 (1984).
  CAS PubMed Google Scholar
• Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E. & Croce, C. M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229, 1390–1393 (1985).
  CAS PubMed Google Scholar
• Gaulard, P. et al. Expression of the bcl-2 gene product in follicular lymphoma. Am. J. Pathol. 140, 1089–1095 (1992).
  CAS PubMed PubMed Central Google Scholar
• Ben-Ezra, J. M., Kornstein, M. J., Grimes, M. M. & Krysal, G. Small cell carcinomas of the lung express the Bcl-2 protein. Am. J. Pathol. 145, 1036–1040 (1994).
  CAS PubMed PubMed Central Google Scholar
• Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H. & Tateishi, R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res. 15, 503–505 (1995).
  CAS PubMed Google Scholar
• Schena, M. et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79, 2981–2989 (1992).
  CAS PubMed Google Scholar
• Harada, N. et al. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 12, 1817–1820 (1998).
  CAS PubMed Google Scholar
• Leiter, U., Schmid, R. M., Kaskel, P., Peter, R. U. & Krahn, G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch. Dermatol. Res. 292, 225–232 (2000).
  CAS PubMed Google Scholar
• Matsushima, H. et al. Combined analysis with Bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol. 158, 2278–2283 (1997).
  CAS PubMed Google Scholar
• Keshgegian, A. A., Johnston, E. & Cnaan, A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am. J. Clin. Pathol. 110, 443–449 (1998).
  CAS PubMed Google Scholar
• Mano, Y. et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur. J. Cancer 35, 1214–1219 (1999).
  CAS PubMed Google Scholar
• Rajkumar, T. et al. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur. J. Gynaecol. Oncol. 19, 556–560 (1998).
  CAS PubMed Google Scholar
• Ye, D. et al. Bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J. Urol. 160, 2025–2028 (1998).
  CAS PubMed Google Scholar
• Nakata, B. et al. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology 55, 543–547 (1998).
  CAS PubMed Google Scholar
• Fries, H. et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann. Surg. 228, 780–787 (1998).
  Google Scholar
• Lipponen, P. et al. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J. Pathol. 177, 49–55 (1995).
  CAS PubMed Google Scholar
• Le, M. G. et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int. J. Cancer 84, 562–567 (1999).
  CAS PubMed Google Scholar
• Nakopoulou, L. et al. bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining. Histopathology 34, 310–319 (1999).
  CAS PubMed Google Scholar
• Sinicrope, F. A., Hart, J., Michelassi, F. & Lee, J. J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin. Cancer Res. 1, 1103–1110 (1995).
  CAS PubMed Google Scholar
• Ofner, D. et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer 72, 981–985 (1995).
  CAS PubMed PubMed Central Google Scholar
• Baretton, G. B. et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77, 255–264 (1996).
  CAS PubMed Google Scholar
• Leahy, D. T., Mulcahy, H. E., O'Donoghue, D. P. & Parfrey, N. A. bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology 35, 360–367 (1999).
  CAS PubMed Google Scholar
• Ohmori, T. et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun. 192, 30–36 (1993).
  CAS PubMed Google Scholar
• Minn, A. J., Rudin, C. M., Boise, L. H. & Thompson, C. B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86, 1903–1910 (1995).
  CAS PubMed Google Scholar
• Harima, Y. et al. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J. Cancer Res. Clin. Oncol. 124, 503–510 (1998).
  CAS PubMed Google Scholar
• Mackey, T. J., Borkowski, A., Amin, P., Jacobs, S. C. & Kyprianou, N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52, 1085–1090 (1998).
  CAS PubMed Google Scholar
• Amundson, S. A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101–6110 (2000). Support for BCL-X L as a cancer target.
  CAS PubMed Google Scholar
• Klasa, R. J., Gillum, A. M., Klem, R. E. & Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12, 193–213 (2002). Summary of the use of BCL2 antisense in anticancer treatment.
  CAS PubMed Google Scholar
• Cummings, J., Ward, T. H., Ranson, M. & Dive, C. Apoptosis pathway-targeted drugs — from the bench to the clinic. Biochim. Biophys. Acta 1705, 53–66 (2004).
  CAS PubMed Google Scholar
• Gleave, M. E. & Monia, B. P. Antisense therapy for cancer. Nature Rev. Cancer 5, 468–479 (2005).
  CAS Google Scholar
• Frantz, S. Lessons learnt from Genasense's failure. Nature Rev. Drug Discov. 3, 542–543 (2004).
  CAS Google Scholar
• Agrawal, S. & Kandimalla, E. R. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets 1, 197–209 (2001).
  CAS PubMed Google Scholar
• Zangemeister-Wittke, U. et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-XL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6, 2547–2555 (2000).
  CAS PubMed Google Scholar
• Holinger, E. P., Chittenden, T. & Lutz, R. J. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome _c_-independent activation of caspases. J. Biol. Chem. 274, 13298–13304 (1999).
  CAS PubMed Google Scholar
• Wang, J. L. et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 60, 1498–1505 (2000).
  CAS PubMed Google Scholar
• Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466–1470 (2004).
  CAS PubMed PubMed Central Google Scholar
• Kutzki, O. et al. Development of a potent Bcl-xL antagonist based on α-helix mimicry. J. Am. Chem. Soc. 124, 11838–11839 (2002).
  CAS PubMed Google Scholar
• Tzung, S. P. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol. 3, 183–191 (2001).
  CAS PubMed Google Scholar
• Chan, S. L. et al. Identification of chelerythrine as an inhibitor of BclXL function. J. Biol. Chem. 278, 20453–20456 (2003).
  CAS PubMed Google Scholar
• Real, P. J. et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res. 64, 7947–7953 (2004).
  CAS PubMed Google Scholar
• Wang, J. L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124–7129 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kitada, S. et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 46, 4259–4264 (2003).
  CAS PubMed Google Scholar
• Mohammad, R. M. et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(–)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther. 4, 13–21 (2005).
  CAS PubMed Google Scholar
• Oliver, C. L. et al. (–)-Gossypol acts directly on the mitochondria to overcome Bcl-2 and Bcl-X(L)-mediated apoptosis resistance. Mol. Cancer Ther. 4, 23–31 (2005).
  CAS PubMed Google Scholar
• Degterev, A. et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nature Cell Biol. 3, 173–182 (2001).
  CAS PubMed Google Scholar
• Enyedy, I. J. et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 44, 4313–4324 (2001).
  CAS PubMed Google Scholar
• Becattini, B. et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-xL. Chem. Biol. 11, 389–395 (2004).
  CAS PubMed Google Scholar
• Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005). Discovery of the most potent BCL2-family inhibitor to date.
  CAS PubMed Google Scholar
• Sun, C. et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 401, 818–822 (1999).
  CAS PubMed Google Scholar
• Takahashi, R. et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273, 7787–7790 (1998).
  CAS PubMed Google Scholar
• Riedl, S. J. et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 104, 791–800 (2001).
  CAS PubMed Google Scholar
• Sun, C. et al. NMR structure and mutagenesis of the third bir domain of the inhibitor of apoptosis protein XIAP. J. Biol. Chem. 275, 33777–33781 (2000).
  CAS PubMed Google Scholar
• Shiozaki, E. N. et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11, 519–527 (2003).
  CAS PubMed Google Scholar
• Liu, Z. et al. Structural basis for binding of smac/DIABLO to the XIAP bir3 domain. Nature 408, 1004–1008 (2000). This reference, with reference 100, describes the structure of the SMAC–XIAP-BIR3 complex used in the design of XIAP antagonists.
  CAS PubMed Google Scholar
• Wu, G. et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 408, 1008–1012 (2000).
  CAS PubMed Google Scholar
• LaCasse, E. C., Baird, S., Korneluk, R. G. & MacKenzie, A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247–3259 (1998).
  PubMed Google Scholar
• Hu, Y. et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer c in vitro and in vivo. Clin. Cancer Res. 9, 2826–2836 (2003).
  CAS PubMed Google Scholar
• Arnt, C. R., Chiorean, M. V., Heldebrant, M. P. Gores, G. J. & Kaufmann, S. H. Synthetic smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277, 44236–44243 (2002).
  CAS PubMed Google Scholar
• Yang, L. et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated smac peptide. Cancer Res. 63, 831–837 (2003).
  CAS PubMed Google Scholar
• Sun, H. et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J. Med. Chem. 47, 4147–4150 (2004).
  CAS PubMed Google Scholar
• Sun, H. et al. Structure-based design of potent, conformationally constrained Smac mimetics. J. Am. Chem. Soc. 126, 16686–16687 (2004).
  CAS PubMed Google Scholar
• Sun, H. et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg. Med. Chem. Lett. 15, 793–797 (2005).
  CAS PubMed Google Scholar
• Oost, T. et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47, 4417–4426 (2004).
  CAS PubMed Google Scholar
• Wu, T. Y. H., Wagner, K. W., Bursulaya, B., Schultz, P. G. & Deveraux, Q. L. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem. Biol. 10, 759–767 (2003).
  CAS PubMed Google Scholar
• Nikolovska-Coleska, Z. et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47, 2430–2440 (2004).
  CAS PubMed Google Scholar
• Li, L. et al. A small molecule smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 305, 1471–1474 (2004).
  CAS PubMed Google Scholar
• Park, C. et al. Non-peptidic small molecule inhibitors of XIAP. Bioorg. Med. Chem. Lett. 15, 771–775 (2005).
  CAS PubMed Google Scholar
• Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25–35 (2004).
  CAS PubMed Google Scholar
• Ambrosini, G., Adida, C. & Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917–921 (1997). The first report of survivin.
  CAS PubMed Google Scholar
• Altieri, D. C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581–8589 (2003).
  CAS PubMed Google Scholar
• Olie, R. A. et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60, 2805–2809 (2000).
  CAS PubMed Google Scholar
• Grossman, D., Kim, P. J., Schechner, J. S. & Altieri, D. C. Inhibition of melanoma tumor growth in vivo by survivin target. Proc. Natl Acad. Sci. USA 98, 635–640 (2001).
  CAS PubMed PubMed Central Google Scholar
• Momand, J., Wu, H. H. & Dasgupta, G. MDM2 — master regulator of the p53 tumor suppressor protein. Gene 242, 15–29 (2000).
  CAS PubMed Google Scholar
• Lane, D. P. & Lain, S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 8 (Suppl.), S38–S42 (2002).
  CAS PubMed Google Scholar
• Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948–953 (1996). Structure of the p53–MDM2 complex used in the design of MDM2 inhibitors.
  CAS PubMed Google Scholar
• Bottger, A. et al. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269, 744–756 (1997).
  CAS PubMed Google Scholar
• Stoll, R. et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2, 336–344 (2001).
  Google Scholar
• Zhao, J. et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183, 69–77 (2002).
  CAS PubMed Google Scholar
• Duncan, S. J. et al. Isolation and structure elucidation of chlorofusin, a novel p53–MDM2 antagonist from a Fusarium sp. J. Med. Chem. Soc. 123, 554–560 (2001).
  CAS Google Scholar
• Galatin, P. S. & Abraham, D. J. A nonpeptidic sulfonamide inhibits the p53–mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. 47, 4163–4165 (2004).
  CAS PubMed Google Scholar
• Parks D. J. et al. 1,4–Benzodiazepine–2,5-diones as small molecule antagonists of the HDM2–p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 15, 765–770 (2005).
  CAS PubMed Google Scholar
• Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004). Discovery of the most potent MDM2 inhibitor to date.
  CAS PubMed Google Scholar
• Workman, P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem. Soc. Trans. 32, 393–396 (2004).
  CAS PubMed Google Scholar
• Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231–241 (1997).
  CAS PubMed Google Scholar
• del Paso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687–689 (1997).
  Google Scholar
• Blume-Jensen, P., Janknecht, R. & Hunter, T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8, 779–782 (1998).
  CAS PubMed Google Scholar
• Kim, A. H., Khursigara, G., Sun, X., Franke, T. F. & Chao, M. V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase Mol. Cell. Biol. 21, 893–901 (2001).
  CAS PubMed PubMed Central Google Scholar
• Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857–868 (1999).
  CAS PubMed Google Scholar
• Kops, G. J. & Burgering, B. M. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J. Mol. Med. 77, 656–665 (1999).
  CAS PubMed Google Scholar
• Kops, G. J. et al. Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 398, 630–634 (1999).
  CAS PubMed Google Scholar
• Gelfanov, V. M. et al. Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor κB-mediated antiapoptosis involving c-IAP2. Blood 98, 2508–2517 (2001).
  CAS PubMed Google Scholar
• Trencia, A. et al. Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol. Cell. Biol. 23, 4511–4521 (2003).
  CAS PubMed PubMed Central Google Scholar
• Mitsiades, C. S., Mitsiades, N. & Koutsilieris, M. The akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets 4, 235–256 (2004).
  CAS PubMed Google Scholar
• Lu, Y., Wang, H. & Mills, G. B. Targeting PI3K–akt pathway for cancer therapy. Rev. Clin. Exp. Hematol. 7, 205–228 (2003).
  CAS PubMed Google Scholar
• Luo, Y. et al. Potent and selective inhibitors of akt kinases slow the progression of tumors in vivo. Mol. Cancer Therap. 4, 977–986 (2005).
  CAS Google Scholar
• Rowinsky, E. K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16, 564–575 (2004).
  CAS PubMed Google Scholar
• Adams, J. The proteasome: a suitable antineoplastic target. Nature Rev. Cancer 4, 349–360 (2004).
  CAS Google Scholar
• Fribley, A., Zeng, Q. & Wang, C. Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinomous cells. Mol. Cell. Biol. 24, 9696–9704 (2004).
  Google Scholar
• Burke, J. R. Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr. Opin. Drug Discov. Devel. 6, 720–728 (2003).
  CAS PubMed Google Scholar
• Chen, G. -Q. et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 88, 1052–1061 (1996).
  CAS PubMed Google Scholar